Reappraisal of the role of dolasetron in prevention and treatment of nausea and vomiting associated with surgery or chemotherapy

References

• TriggMEHigaGMChemotherapy-induced nausea and vomiting: antiemetic trials that impacted clinical practiceJ Oncol Pharm Pract20101623324420085961
   PubMedGoogle Scholar
• HamadaniMChaudharyLAwanFTManagement of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?J Oncol Pharm Pract200713697517873106
   PubMedGoogle Scholar
• NavariRMPharmacological management of chemotherapy-induced nausea and vomitingDrugs20096951553319368415
   PubMed Web of Science ®Google Scholar
• BotrelTEAClarkOACClarkLEfficacy of palonosetron (pal) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysisSupport Care Cancer20111982383220495832
   PubMed Web of Science ®Google Scholar
• Anesthesia Quality InstituteAnesthesia in the United States2009 Available from: www.aqihq.orgAccessed February 10, 2012
   Google Scholar
• GanTJMeyerTApfelCCConsensus guidelines for managing postoperative nausea and vomitingAnesth Analg200397627112818945
   PubMed Web of Science ®Google Scholar
• JanickiPKCytochrome P450 2D6 metabolism and 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomitingMed Sci Monit200511RA32223816192915
   PubMed Web of Science ®Google Scholar
• GregoryREEttingerDS5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomitingDrugs1998551731899506240
   PubMed Web of Science ®Google Scholar
• BalfourJAGoaKLDolasetron: a review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgeryDrugs1997542732989257083
   PubMed Web of Science ®Google Scholar
• AaproMBlowerP5-hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesisCancer200510411315929119
   PubMed Web of Science ®Google Scholar
• MillerDRArrhythmogenic potential of antiemetics: perspectives on risk-benefitsCan J Anesth20035021522012620941
   PubMed Web of Science ®Google Scholar
• BenedictCRArbogastRMartinLSingle-blind study of the effects of intravenous dolasetron mesylate versus ondansetron on electrocardiographic parameters in normal volunteersJ Cardiovasc Pharmacol2006285359
   Web of Science ®Google Scholar
• KuryshevYABrownAMWangLInteractions of the 5- hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channelsJ Pharmacol Exp Ther200029561462011046096
   PubMed Web of Science ®Google Scholar
• KeefeDLThe cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: is there cause for concern?Oncologist20027657211854548
   PubMed Web of Science ®Google Scholar
• BaltzerLKrisMGHinkleyLReversible electrocardio-graphic interval prolongations following the specific serotonin antagonists ondansetron (OND) and dolasetron mesylate (DM): a possible drug class effect without sequelae?Proc Am Soc Clin Oncol199413433a
   Google Scholar
• CubedduLXIatrogenic CT abnormalities and fatal arrhythmias: mechanisms and clinical significanceCurr Cardiol Rev2009516617620676275
   PubMedGoogle Scholar
• HuntTLCramerMShahAA double-blind, placebo-controlled, dose-ranging safety evaluation of single-dose intravenous dolasetron in healthy male volunteersJ Clin Pharmacol1995357057127560251
   PubMed Web of Science ®Google Scholar
• KantorGArrhythmia risk of antiemetic agentsAnesthesiology20029728612131144
   PubMed Web of Science ®Google Scholar
• KellerGAPonteMLDi GirolamoGOther drugs acting on nervous system associated with QT-interval prolongationCurr Drug Saf2010510511120210727
   PubMedGoogle Scholar
• QuraishiSASchulerGHJanickiPK5HT(3)-receptor antagonists and cardiac repolarization time in patients expressing a novel genetic target associated with baseline QTc interval abnormalitiesJ Clin Anesth20112329730221663814
   PubMed Web of Science ®Google Scholar
• CharbitBAlbaladejoPFunck-BrentanoCProlongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetronAnesthesiology20051021094110015915019
   PubMed Web of Science ®Google Scholar
• KasinathNSMalakOTetzlaffJAtrial fibrillation after ondansetron for the prevention and treatment of postoperative nausea and vomiting: a case reportCan J Anaesth20035022923112620943
   PubMed Web of Science ®Google Scholar
• HeskethPNavariRGroteTDouble-bind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancerJ Clin Oncol199614224222498708713
   PubMed Web of Science ®Google Scholar
• EisenbergPFigueroa-VadilloJZamoraRImproved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonistCancer2003982473248214635083
   PubMed Web of Science ®Google Scholar
• PhilipBKMcLeskeyCHChellyJEPooled analysis of three large clinical trials to determine the optimal dose of dolasetron mesylate needed to prevent postoperative nausea and vomiting. The dolasetron prophylaxis study groupJ Clin Anesth2000121810773500
   PubMed Web of Science ®Google Scholar
• GroteTHPinedaLFFiglinRAOral dolasetron mesylate in patients receiving moderately emetogenic platinum-containing chemotherapy. Oral Dolasetron Dose Response Study GroupCancer J Sci Am1997345519072308
   PubMed Web of Science ®Google Scholar
• RubensteinEBGrallaRJHainsworthJDRandomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy. Oral Dolasetron Dose-Response Study GroupCancer199779121612249070501
   PubMed Web of Science ®Google Scholar
• MandanasRABeveridgeRRifkinRMA randomized, multicenter, open-label comparison of the antiemetic efficacy of dolasetron versus ondansetron for the prevention of nausea and vomiting during high-dose myeloablative chemotherapySupport Cancer Ther2005211412118628198
   PubMedGoogle Scholar
• LoftersWSPaterJLZeeBPhase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapyJ Clin Oncol199715296629739256141
   PubMed Web of Science ®Google Scholar
• PaterJLLoftersWSZeeBThe role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapyAnn Oncol199781811859093728
   PubMed Web of Science ®Google Scholar
• AudhuyBCappelaerePMartinMA double-blind, randomized comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapyEur J Cancer199632A8078139081358
   PubMed Web of Science ®Google Scholar
• RoilaFBallatoriETonatoM5-HT3 receptor antagonists: differences and similaritiesEur J Cancer199733136413709337675
   PubMed Web of Science ®Google Scholar
• BirminghamSDMecklenburgBWLujanEDolasetron versus ondansetron as single-agent prophylaxis for patients at increased risk for postoperative nausea and vomiting: a prospective, double-blind, randomized trialMil Med200617191391617036618
   PubMed Web of Science ®Google Scholar
• SteinerMYorgasonRZVermeulenLCPatient outcomes after therapeutic interchange of dolasetron for granisetronAm J Health Syst Pharm2003601023102812789874
   PubMed Web of Science ®Google Scholar
• TanMXuRSethRGranisetron vs dolasetron for acute chemotherapy- induced nausea and vomiting (CINV) in high and moderately high emetogenic chemotherapy: an open-label pilot studyCurr Med Res Opin20042087988215200746
   PubMed Web of Science ®Google Scholar
• SchwartzbergLJacksonJJainGImpact of 5-HT3RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomitingExpert Rev Pharmacoecon Outcomes Res20111148148821711119
   PubMed Web of Science ®Google Scholar
• RochfordMKiernanTJAzizADolasetron overdose resulting in prolonged QTc interval and severe hypotension: a case report and literature reviewEmerg Med J20072451551717582056
   PubMed Web of Science ®Google Scholar
• HigginsDJBunkerNJDolasetron and peri-operative cardiac arrhythmiaAnaesthesia20056093693716115265
   PubMed Web of Science ®Google Scholar
• TurnerSMathewsLPandharipandePDolasetron-induced torsades de pointesJ Clin Anesth20071962262518083478
   PubMed Web of Science ®Google Scholar
• RodenDMDrug induced prolongation of the QT intervalN Engl J Med20043501013102214999113
   PubMed Web of Science ®Google Scholar
• AlgraATijssenJGRoelandtJRQTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrestCirculation199183188818942040041
   PubMed Web of Science ®Google Scholar
• GoodinSCunninghamR5-HT3-receptor antagonists for the treatment of nausea and vomiting: a reappraisal of their side-effect profileOncologist2002742443612401905
   PubMed Web of Science ®Google Scholar
• Food and Drug AdministrationFDA drug safety communication: Abnormal heart rhythms associated with use of Anzemet (dolasetron mesylate) Available from: http://www.fda.gov/Drugs/DrugSafety/ucm237081.htmAccessed November 10, 2011
   Google Scholar
• SchnellFMCoopAJAn evaluation of potential signals for ventricular arrhythmia and cardiac arrest with dolasetron, ondansetron, and granisetron in the FDA combined spontaneous reporting system/adverse event reporting systemCurr Ther Res Clin Exp20056640941924790242
   PubMed Web of Science ®Google Scholar
• Food and Drug AdministrationGuidance for Industry E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugsRockville, MDUS Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research2005
   Google Scholar
• BlumKIs QT prolongation a valid reason to abandon Zofran?Anesth News201137158
   Google Scholar